Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients
Table 3
Meta-analysis of the association between CEA or CA15-3 and clinicopathological features of breast cancer.
Variables
CEA
CA15-3
Number of studies
Number of patients
OR (95% CI)
P
Heterogeneity I2 (%)
Heterogeneity Ph
Mode
Number of studies
Number of patients
OR (95% CI)
P
Heterogeneity I2 (%)
Heterogeneity Ph
Mode
Age (≤35 versus >35)
3
1210
0.52 (0.29–0.94)
0.03
10
0.33
Fixed
3
1251
1.83 (1.20–2.80)
0.005
0
0.87
Fixed
Menopause (no versus yes)
3
792
0.75 (0.33–1.69)
0.49
62
0.07
Random
5
1524
1.16 (0.90–1.50)
0.25
19
0.29
Fixed
Tumor size (≤5 cm versus >5 cm)
5
1385
0.28 (0.13–0.57)
<0.001
69
0.01
Random
9
2766
0.42 (0.29–0.63)
<0.001
62
0.007
Random
Lymph node metastasis (no versus yes)
6
3497
0.44 (0.36–0.53)
<0.001
13
0.33
Fixed
9
4867
0.59 (0.38–0.93)
0.02
84
<0.001
Random
TNM stage (I-II versus III-IV)
7
4706
0.39 (0.25–0.60)
<0.001
77
0.0002
Random
10
5298
0.34 (0.20–0.58)
<0.001
88
<0.001
Random
Histological grade (I-II versus III)
5
2693
0.87 (0.58–1.31)
0.50
53
0.07
Random
8
3980
0.63 (0.46–0.87)
0.005
64
0.006
Random
ER (no versus yes)
5
3047
0.75 (0.41–1.38)
0.36
81
0.0003
Random
8
4194
1.23 (0.93–1.61)
0.14
50
0.05
Random
PR (no versus yes)
3
2622
0.83 (0.47–1.46)
0.52
78
0.01
Random
7
3810
1.01 (0.86–1.18)
0.95
0
0.91
Fixed
HER-2 (no versus yes)
2
730
0.67 (0.25–1.78)
0.42
83
0.01
Random
5
1305
1.11 (0.83–1.47)
0.48
0
0.76
Fixed
Luminal type (no versus yes)
3
1200
0.72 (0.37–1.39)
0.33
63
0.07
Random
4
1396
1.32 (0.77–2.22)
0.31
65
0.04
Random
HER-2 overexpress type (no versus yes)
3
1200
0.78 (0.32–1.89)
0.57
67
0.05
Random
4
1396
0.75 (0.50–1.14)
0.18
46
0.13
Fixed
Triple-negative type (no versus yes)
3
1200
2.08 (1.30–3.33)
0.003
52
0.12
Fixed
4
1396
0.91 (0.65–1.28)
0.59
0
0.51
Fixed
OR: odds ratio; 95% CI: 95% confidence interval; Ph: values of Q for heterogeneity test; ER: estrogen receptor; PR: progesterone receptor; HER-2: human epidermal growth factor receptor 2.